The clinical development of a candidate p38 kinase inhibitor was terminated because of its unexpectedly rapid clearance in human subjects. Its short halflife and metabolic profile in human beings were vastly different from that in rats, dogs, and monkeys characterized during routine pre-clinical studies. Mice generated the predominant drug (4-hydroxylated) metabolite produced in human beings, which was not found in other species. The data from a murine in vitro drug biotransformation assay that used liver extracts from 14 inbred mouse strains were analyzed by haplotype-based computational genetic analysis. This led to the identification of aldehyde oxidase-1 (AOX1) as the enzyme responsible for the rapid metabolism of this drug. Specific enzyme inhibitors and expressed recombinant enzymes were used to confirm that AOX catalyzed the formation of the 4-hydroxylated drug metabolite in mouse and man. Genetic variation within Aox1 regulated the level of hepatic Aox1 mRNA, AOX1 protein, and enzyme activity among the inbred strains. Thus, computational murine pharmacogenetic analysis can facilitate the identification and characterization of drug metabolism pathways that are differentially utilized by humans and other species.
Introduction
Drug development is an extremely complicated, costly, and time-consuming process. Poor bioavailability or metabolic stability of a candidate drug has contributed to failures in drug development. Therefore, the pharmacokinetic profile of a drug candidate is comprehensively assessed during pre-clinical development using in vitro systems and in several different animal species before it is administered to human subjects (reviewed in Singh 1 ). The data obtained from animal studies are then extrapolated to predict the human pharmacokinetic profile through allometric modeling, which assumes that anatomical, physiological, and biochemical variables can be scaled across mammalian species as a power function of the body weight. 2 However, allometric predictions do not adjust for inter-species differences within drug metabolizing enzymes, which can cause substantial inter-species differences in drug metabolism, as has been observed for the cytochrome P450 family. [3] [4] [5] Despite the existence of multiple different strains within many of the species (rat, mouse, or dog) used for pharmacokinetic testing, data are usually obtained from only a single strain.
As there is significant variability in drug metabolism among different strains of rats and mice, [6] [7] [8] pharmacokinetic data generated from one strain may be atypical and may not even represent the pharmacokinetic profile of most strains of that species.
Therefore, it is critical to develop tools that provide information about the genetic basis for inter-individual or inter-species differences in drug metabolism. We recently described how in vivo pharmacokinetic studies 9 or a hepatic in vitro drug biotransformation system 10 could be used in conjunction with haplotype-based computational genetic analysis [11] [12] [13] [14] to quickly identify genetic factors affecting the metabolism of commonly prescribed drugs in mice. To do this, a test drug is administered to multiple inbred strains, or incubated with hepatic extracts in vitro, and then individual drug metabolites are measured at multiple time points. The causal genetic factors are identified by correlating interstrain differences in drug metabolism with the pattern of genetic variation within genomic regions among the inbred strains. Multiple pathways mediate the metabolism of most drugs, and distinct enzymes may catalyze individual steps in each pathway. Therefore, analysis of the rate of formation of individual metabolites across multiple inbred murine strains reduced the complexity of this biological process, which enabled the genetic factors that contribute to the overall variability in drug metabolism to be identified (reviewed in Liao et al. 15 ). Here, the in vitro and in silico genetic analysis method was used to analyze the metabolism of a novel p38 kinase inhibitor, whose clinical development for treatment of rheumatoid arthritis was terminated because of rapid drug metabolism in human subjects. Its short half-life and metabolic profile were not predicted by its pharmacokinetics in several animal species analyzed during pre-clinical evaluation. However, murine in vitro computational genetic analysis identified the cause of its unusual pharmacokinetic and metabolic profile in human subjects.
Materials and methods
Phase I clinical trial A single-center, ascending single-dose, randomized, observer-blinded, parallel-design phase I study was performed according to a protocol that was approved by the Institutional Review Board at Biokinetic Europe (Belfast, UK) that followed the Helsinki guidelines. Six healthy male subjects (18-43 years of age) received RO1 (50 mg), and 2 received placebo in an oral solution. Peripheral blood samples were collected from all subjects 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 h after dosing, and then daily for 7 days. This initial drug dose was selected based on allometric projection of human exposures from animal pK data. It was anticipated that this dose would produce a blood level above the measured IC50 of this drug for inhibition of TNFa-induced-IL1b production in human whole blood. The plasma concentration of RO1 and its metabolites were analyzed by LC/MS/MS analysis as described below.
Pre-clinical pharmacokinetics and projection of human dose All animal experiments were implemented under protocols approved by the Roche Palo Alto Institutional Animal Care and Use Committee. For the pharmacokinetics studies, Hanover-Wistar rats were obtained from Charles Rivers Laboratories; beagle dogs and cynomolgus monkeys were obtained from other commercial suppliers. All animals were housed in a pathogen-free environment and provided food and water ad libitum with a 12 h:12 h light/dark cycle. All animals were acclimatized for an additional week before study. The animals were administered a single intravenous dose of RO1 (5 mg kg -1 ) in a simple aqueous formulation and blood samples were collected into heparinized tubes from a minimum of three animals per study at prescribed times.
For allometric scaling, the dose-normalized plasma concentration in each animal species is adjusted for clearance by dividing the time by BW 0.25 , where BW is body weight (kg). The concentration-time curves obtained from these animals were converted into a human concentrationtime curve using the elementary Dedrick plot with the following equation: [16] [17] [18] [19] 
where x ¼ 0.75 Chemicals RO1, RO2, and its metabolites (RO1: Preparation and analysis of human liver cytosol Segments of three frozen postmortem livers were obtained from Science Care (Phoenix, Arizona, USA). Approximately 2 g of liver tissues from donors 1 (male), 2 (male), and 3 (female) were each homogenized in three volumes of 20 mM Tris buffer (pH 7.4) containing 1 mM EDTA, 1 mM dithiothreitol, and a complete protease inhibitors cocktail tablet (Roche Applied Sciences, Indianapolis, IN, USA). The homogenates were centrifuged at 100 000 g for 65 min. Fat was removed from the resultant supernatants by filtration through gauze tissues and protein concentrations were determined from aliquots of the supernatants by BCA protein assay (Pierce Biotechnology, Rockford, IL, USA). Individual donors activities were initially determined. For screening assays, a pool was made by mixing equal amounts of protein from each of the three cytosol fractions. Aliquots of the cytosol pool were apportioned into vials, and then the vials were stored at À70 1C until use. Human liver cytosols (1 mg ml -1 ) were incubated with substrate RO1 (100 mM), þ 100 mM isonanillin, in Tris (0.05 M, pH 7.4), MgCl (5 mM), and 1.15% KCl for 1 h at 37 1C. All incubations were performed in triplicate. At the end of the incubation, 100 ml of IS were added into each reaction, mixed, and then centrifuged at 10 000 rpm for 10 min to produce clear supernatants. After centrifugation, aliquots (100 ml) of the resultant supernatants were transferred to the 96-deep-well plate and assayed for the hydroxylated metabolites M1 by the LC-MS/MS method described below.
Preparation of murine liver cytosol
Sixteen inbred mouse strains (MRL/MpJ, LG/J, NZW/LaC, 129S1/SvImJ, SM/J, NZB/B1nJ, LP/J, DBA/2, C57BL/6, A/J, C3H/HeJ, BALB/c, B10.D2-H2dH2-T18c Hc0/oSnJ, BALB/ cByJ, AKR/J, A/HeJ), ages 9-10 weeks, were obtained from the Jackson Laboratory and housed at Roche Palo Alto in a pathogen-free facility, and provided food and water ad libitum with a 12 h: 12 h light/dark cycle for at least 2 weeks before experimentation. Three male mice of each strain were euthanized by cervical dislocation, and livers were harvested and snap frozen in liquid nitrogen. Equal amounts of liver from each mouse were pooled and homogenized in three volumes of 20 mM Tris buffer (pH 7.4) supplemented with 1 mM EDTA, 1 mM dithiothreitol, and a complete protease inhibitors cocktail tablet (Roche Applied Sciences).
In preliminary experiments, we were unable to detect production of the M1 metabolite after incubation of RO1 or RO2 with human liver or human intestinal microsomal extracts, murine liver S9 fractions (contain both microsomal and cytosolic fractions), or with cytosolic fractions prepared by conventional methods. Therefore, cytosolic extracts were rapidly isolated using a modified method with a single ultracentrifugation step that minimizes the processing time. 20 To do this, the homogenates were centrifuged at 100 000 g for 65 min at 4 1C. Fat was removed from the supernatants and protein concentrations were determined as above. Liver cytosol aliquots were stored at À80 1C until use.
In vitro drug biotransformation assays
Mouse liver cytosol or cytosolic extracts of insect cells expressing recombinant aldehyde oxidase (AOX) proteins (1 mg ml -1 ) were pre-incubated with PBS buffer (pH 7.2) at a final volume of 100 ml at 37 1C for 5 min. The reactions were initiated by addition of 10 mM RO2. At designated time periods, the reactions (100 ml) were terminated by adding a 100 ml stop solution (40 ng ml -1 camptothecin in acetonitrile). All samples were then centrifuged at 4000 g for 10 min to precipitate the proteins. The supernatant was collected for metabolite analysis by LC/MS/MS. CYP450 activity was assessed by incubating the liver cytosol with 10 mM RO2 and ABT (100 mM) in the presence of Tris (0.05 M, pH 7.4), MgCl (5 mM), and 1.15% KCl with or without NADPH-P450 oxidoreductase (BD Gentest, Bedford, MA, USA). The AOX inhibition assay was carried out under the same conditions as the ABT assay except for the substitution of isovanillin (100 mM to 1 mM) for ABT. The inhibitor reactions were performed in duplicates at 37 1C for 60 min.
LC/MS/MS analysis
The LC/MS/MS system consisted of a Shimadzu LC system, a vacuum degasser, an autoinjector, and a Sciex API 4000 triple quadruple mass spectrometer (MS/MS) (Applied Biosystems, Foster City, CA, USA), and was equipped with Analyst software v. 1.4.1 (Applied Biosystems) for data acquisition and calibration. RO2 and its metabolites were separated on a Thermo BDS Hypersil-C18 column (50 Â 2 mm, 5 mm) with HPLC guard column (Thermo Electron Corp., Bellefonte, PA, USA) at a flow rate of 0.4 ml min -1 . The mobile phases were 5 mM ammonium acetate in 0.1% formic acid (A) and 50% acetonitrile/50% methanol with 0.1% formic acid (B). The gradient of B was as follows: 10% (0-0.5 min), 10-90% (0.5-2.8 min), 90-10% (2.8-3 min), and 10% (3-3.5 min). The injection volume was 10 ml and the total run time was 3. Calibration curves were developed by spiking blank CD1 mouse liver S9 fraction (BD Gentest) with different amounts of RO2 ranging from 1 to 50 000 ng ml -1 . The peak area ratio of metabolites relative to that of the IS (camptothecin) was quantified, and correlation coefficients were calculated by least-square regression analysis.
Computational genetic mapping
The computational genetic analysis of the inbred strain data was performed as described earlier. 11, 12 In brief, a haplotype block map of the mouse genome was constructed, and single-nucleotide polymorphisms (SNPs) were organized into haplotype blocks, which typically consisted of 2-4 haplotypes. 13, 14 The haplotype-based computational analysis identified haplotype blocks in which the haplotypic strain grouping within the block correlates with the distribution of phenotypic data among the inbred strains analyzed. The program calculates a P-value, which assesses the likelihood that genetic variation within each block could underlie the observed distribution of phenotypes among the inbred strains. 11, 13 The haplotype blocks are ranked based on the calculated P-value. The genomic regions within haplotype blocks that strongly correlated with the phenotypic data are then analyzed. The Roche SNP database (http://mousesnp.roche.com) contains 250 837 SNPs generated from 21 inbred mouse strains covering 3346 genes, including 60 Cyp450 enzymes, 8 aldehyde dehydrogenases, 5 flavin monooxygenases, 88 transporters (Abc or Slc gene families), 3 AOXs, almost all UDP glucuronosyltransferase, glutathione S-transferase enzymes, sulfotransferases, and 41 nuclear hormone receptors. The P-values for numerical
Computational in vitro pharmacogenetics X Zhang et al phenotype evaluated in this experiment were calculated as described using ANOVA. 11, 12 As ANOVA-based computation requires homogeneity of variance, the measured rate of M1 metabolite formation for each strain was logarithmically transformed for the analysis.
A relatively large number of genomic regions had a genetic pattern that correlated with the rate of drug metabolism. As computational genetic mapping is based on comparison of phenotypic data with a large number of haplotypic blocks (n ¼ 5255 here), a haplotype distribution pattern can correlate with trait values purely by chance, or because of genetic relatedness among the inbred strains. When the genetic differences within these identified regions do not contribute to the phenotypic differences observed, the association is a 'false-positive' prediction. One can attempt to eliminate false-positive predictions by setting a very high bar for the statistical significance of an identified genomic region. However, this raises the risk of a false negative-spuriously rejecting a true causative genetic factor from consideration. As discussed elsewhere, 21 as we cannot compensate for a false negative, we have chosen to set our statistical significance at a threshold that minimizes the chance of a false negative.
Microarray and RT-PCR gene expression analysis
For analysis of global gene expression patterns in liver, total RNA was isolated from liver obtained from female mice (age 11 weeks) of 10 different inbred strains; mRNA was then isolated from three individual mice for each strain, and 39 000 transcripts present on Affymetrix microarrays (Mouse Genome 430 2.0) array were analyzed in each sample as described earlier. 10 RT-PCR analysis was used to analyze the pattern of expression of AOX genes in liver. Total liver RNA was prepared from female mice as described earlier. 11 The Aox mRNAs were analyzed by Taqman as described by the manufacturer (Applied Biosystems) using the following primers:
Aox1 Recombinant AOX1 expression Aox1 cDNAs were isolated from AHeJ and MRL liver, and human AOX1 from Huh-7 cells by RT-PCR using oligo-dT priming; and cloned into pVL 1392 univ ccdB vector. Recombinant baculovirus was produced using the Rapid Suspension Transfection method with an infection time of 72 h. For protein production, log-phase Sf9 cells (1.2 Â 10 6 per ml) were infected with recombinant virus and grown at 27 1C in SF-900 II medium (Invitrogen, Carlsbad, CA, USA) supplemented 10% heat-inactivated FBS. One hour after infection, a supplement of 0.5 mM NaMoO 4 , 10 mM riboflavin, 10 mM guanosine, and 80 mM FeSO 4 was added to the growth medium. On harvest, Sf9 cells expressing the recombinant cDNAs were re-suspended in a solution containing 50 mM Tris (pH 8), 5 mM DTT, 250 mM NaCl, 0.5 mM EDTA with complete protease inhibitors cocktail tablet (Roche Applied Sciences) and homogenized by sonication. After centrifugation for 20 min at 410 000 rpm at 4 1C, the supernatants were collected for measurement of total protein concentration and then used in the biotransformation assays at a final concentration of 1 mg ml -1 .
Immunoblot and protein quantitation
In all, 40-50 mg of total cellular protein was separated by 10% SDS-PAGE and transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA). After 10 min of blocking in 5% milk in TBS Tween 20 (milk/TBST), the membranes were blotted with primary antibodies (1:1000 or 1:500 dilution in milk/TBST) for 1 h at room temperature or overnight at 4 1C.
After washing in TBST for 10 min, the membranes were incubated with alkaline phosphatase-conjugated a-mouse or rabbit immunoglobulin (Promega, Madison, WI, USA) secondary antibodies for 1 h at room temperature (1:1000 in 5% milk/TBST). After a 30 min wash in TBST, the bands were developed with one-step NBT/BCIP (Pierce, Rockford, IL, USA). The primary antibodies were a-AOX1 (Clone 7 from BD Biosciences Pharmingen, San Diego, CA, USA), or anti-b-actin, rabbit monoclonal (Cell Signaling, Danvers, MA, USA). After developing, the blots were scanned on a flatbed scanner (Hewlett-Packard scanjet 8300, Palo Alto, CA, USA). The signal density for each band was measured by using Image Analysis and Measurement Lab software (http:// brneurosci.org/imal.html) and normalized to the highest density of the same protein. The relative ratio was compared between normalized signal densities. A Spearman's correlation coefficient was calculated using SAS 9 (Cary, NC, USA) software to assess the degree of correlation between AOX activity and the normalized protein values.
Results

Clinical pharmacokinetics of RO1 metabolism
The safety, tolerability, and pharmacokinetics of a novel p38 MAP kinase inhibitor (RO1) for treatment of rheumatoid arthritis ( Figure 1a) were evaluated in six healthy Caucasian male subjects in a phase I clinical study. RO1 (50 mg) or placebo was administered in a single ascending oral dose, randomized, observer-blinded trial, and the plasma concentration of RO1 and its metabolites were measured. Unexpectedly, its observed terminal mean half-life (T 1 2 ) was only 0.7 h (Figure 1a) , and the drug was extensively converted into six measurable metabolites. The drug was metabolized to such a degree that it would not be possible to reach therapeutic levels even at higher doses, which led to discontinuation of clinical development of this compound. The allometric projections were based on pharmacokinetic data obtained from rats (T (Figure 1b) and total exposure level (B20-fold higher) in human subjects. Moreover, the major drug metabolite in human sera was a 4-hydroxylated metabolite (M1) (220% of AUC relative to parent drug) that was rapidly glucuronidated
Computational in vitro pharmacogenetics X Zhang et al (508% of parent drug AUC) and cleared through urinary excretion. Of importance, a negligible amount of this metabolite was formed in the rats, dogs, and monkeys tested, but the other drug metabolites in human plasma were also produced by these animal species (data not shown). This suggests that a metabolic pathway that was not used in rats, dogs, or monkeys was responsible for the unexpectedly rapid metabolism of this drug in human subjects.
Computational in vitro pharmacogenetic analysis
The ring oxidation reaction that introduced a hydroxyl group at the C4 position, which converted RO1 to M1, could be carried out by any enzyme within the following gene families: microsomal cytochrome P450 enzymes, alcohol dehydrogenases, AOXs, or xanthine oxidase. Owing to the large number of possibilities, we investigated whether our previously described in vitro murine computational pharmacogenetic analysis method 10 could provide information about how RO1 was biotransformed into M1. To avoid the regulatory requirements and complications associated with working with a compound that was undergoing active clinical testing at the time, RO2, a diastereomer of RO1 (Figure 1a ) that had the same metabolic profile as RO1, was used in some of the initial exploratory murine experiments. We found that cytosolic extracts that were rapidly isolated using modified method 20 mediated the formation of a significant amount of M1 (Figure 2a) . As in human plasma, a full-scale MS scan on the products formed after the in vitro incubation indicated that the M1 was the predominant metabolite formed (data not shown). Unlike human plasma, glucuronidated metabolites were not formed after any in vitro incubation with the murine extracts under any conditions tested. The rate of M1 formation after RO2 (10 mM) was incubated with liver cytosol fractions prepared from 14 inbred mouse strains was monitored by LC/MS/MS analysis (Figure 2a ). For the computational haplotype-based genetic analysis, the amount of M1 formed after 15 min of incubation was analyzed because this time point was within the linear range for this enzymatic reaction and there were significant inter-strain differences in the rate of M1 formation (Figure 2b) . The computational genetic analysis of these data identified 126 haplotype blocks with a P-value o0.05 (Supplementary Table 1 ). A two-step filtering process used was applied to narrow the number of candidate genes that could be responsible for the inter-strain differences. First, a search of the functional annotations within the Genome Ontology Database (http://www.geneontology.org) indicated that only six of these haplotype blocks (shown in Figure 2c ) encoded enzymes that could perform the ring oxidation reaction that generated the 4-hydroxy drug metabolite. Second, we evaluated whether the remaining gene candidates were expressed in the liver. Although Cyp19a1 and Cyp46a1 had correlated genetic patterns, Cyp19a1 mRNA was not detected in any, and Cyp46a1 mRNA was only detected (at a very low level) in 2 of the 12 inbred strains whose livers were examined. As these two enzymes were not expressed in liver of the inbred strains that mediated M1 formation, they were eliminated from consideration. This quickly narrowed the search for candidate genes to two cytochrome P450 genes (Cyp2f2, Cyp2d10) and the AOX genes. Of note, the AOXs were the only enzymes in the molybdenum hydroxylase family with a correlated genetic pattern.
Murine AOX1 mediates M1 generation
To determine whether Cyp450 or AOX enzymes covert RO2 to M1, in vitro biotransformation reactions were performed in the presence of 1-ABT 22, 23 or isovanillin, 24 which are specific inhibitors of Cyp450 or AOX enzymes, respectively. The inhibitors were evaluated using cytosolic extracts from six strains with high, medium, or low rates of M1 formation. As Cyp450 enzyme catalyzed reactions require NADPH as cofactors, all reactions were carried out in the presence and absence of NADPH. ABT did not inhibit M1 formation, Computational in vitro pharmacogenetics X Zhang et al whereas isovanillin completely abolished the conversion of RO2 to M1 in all strains (Figure 3 ). These results suggest that an AOX, and not a Cyp450 enzyme, mediated RO2 biotransformation to M1.
Three co-linear genes (Aox1, Aox3, and Aox4), which encode different AOXs of similar size (1333, 1335, and 1336 amino acids, respectively), are within or immediately adjacent to the computationally correlated haplotype block at 58 Mb on chromosome 1. Although multiple haplotype blocks with a slightly different haplotype pattern span the three AOX genes, there is an extended haplotypic pattern across these three genes. The A/HeJ, A/J, AKR, B10.D2, C57BL6, SMJ, and C3H strains share one haplotype across this region, although the BALB/b and MRL strains share the other haplotype. The Aox1 and Aox3 mRNAs are abundantly expressed in mouse liver, whereas Aox4 mRNA was not expressed in liver (Supplementary Figure 1) . The two remaining candidates, Aox1 and Aox3, had very similar patterns of genetic variation (Supplementary Figure 2) . As an SNP within Aox1 induced an amino-acid change at position 857 (D857E), we examined the ability of two different allelic forms (D857 and E857) of expressed recombinant murine AOX1 to convert RO2 to M1. Despite the amino-acid difference, both allelic forms of AOX1 efficiently catalyzed the biotransformation (Figure 4) .
We next investigated whether the genetic differences altered the level of hepatic Aox1 mRNA, protein expression or enzyme activity. AOX1 enzyme activity (rate of M1 The amount of 4-hydroxy M1 metabolite formed after incubation of RO2 (10 mM) with liver cytosol (1 mg ml -1 total protein) preparations obtained from the indicated mouse strains was determined by LC/MS/MS analysis and is plotted as a function of time. Each data point represents the average ± s.e.m. of three independent measurements performed on liver cytosol preparations for each strain. A blank sample containing water and a liver S9 fraction from CD-1 mice were also run in parallel. (b) The amount of M1 formed after 15 min of incubation with cytosol preparations from 14 strains. (c) The data in (b) was log transformed and analyzed using the haplotype-based computational genetic method. Listed in this table are the genes whose haplotype block pattern significantly correlated with the inter-strain differences in the rate of M1 formation (Po0.05) and have enzymatic activities that could mediate the M1 production. For each block, the chromosomal location, number of SNPs within a block, its gene symbol, and an indicator of gene expression in liver are shown. A colored block represents the haplotype for each strain. Strains with the same colored block share the same haplotype for the particular gene. The haplotype blocks are presented in the same order as indicated in the x axis of (b). The calculated P-value measures the probability that strain groupings within an individual block would have the same degree of association with the phenotypic data by random chance. The hepatic expression level of each gene is also indicated: 'Yes' indicates the gene is expressed in all the strains, 'No' indicates the gene is expressed in none (or o3) of the strains, whereas 'unknown' indicates no information is available. A complete list of all correlated haplotype blocks (P-valueo0.05) is shown in Supplementary Table 1.
M1 Formation
Control Isovanillin
Log 10 (M1 Formed) formation) and protein expression (immunoblotting and densitometry) were simultaneously measured in cytosolic extracts prepared from eight inbred mouse strains representing three haplotypes ( Figure 5 ). Consistent with LPJ having a unique haplotype, the level of hepatic AOX1 protein was lower in LPJ liver than in the strains with the BALB/b haplotype. A Wilcoxon's rank sum test indicated that the amount of hepatic Aox1 mRNA was significantly different between the strains with the SMJ and BALB/b haplotypes (P-value ¼ 0.005). A Spearman's correlation analysis indicated that Aox1 mRNA and AOX1 protein levels were significantly correlated (r ¼ 0.83, P ¼ 0.015) and that AOX1 enzyme activity was significantly correlated with the amount of AOX1 protein in the cytosol (r ¼ 0.95, P ¼ 0.001). Taken together, these results indicate that there are genetically determined differences in hepatic Aox1 mRNA, AOX1 protein, and enzyme activity levels among the inbred strains; and these differences affect the rate of biotransformation of RO2.
Human AOX1 mediates M1 formation
This analysis was undertaken to identify the enzyme that converted the kinase inhibitor to its 4-hydroxy metabolite (M1) in human subjects. On the basis of the murine results, we investigated whether cytosolic preparations from human liver could generate M1. Conventional preparations of human hepatic S-9 or cytosolic fractions lacked appreciable activity, which was probably because of proteolysis during centrifugation. Therefore, a rapid procedure for preparing the cytosolic fraction was developed, which used protease inhibitors and anti-oxidants to preserve enzyme activity. Although there was some variability in the rate of conversion, human liver cytosol fractions that were prepared from three different donors by this method were able to convert RO1 to M1. A kinetic analysis performed on pooled human liver cytosol indicated that RO1 was a low-affinity substrate for the human cytosolic enzyme (Km ¼ 112 mM) (Supplementary Figure 3) . However, virtually all (499%) of the M1 formation catalyzed by the liver cytosolic extract was inhibited by addition of an AOX inhibitor (isovanillin) to the reaction (Figure 6) .
A human AOX1cDNA, which is the human homolog of murine Aox1, was expressed in insect cells. Cytosolic extracts prepared from these insect cells efficiently catalyzed the biotransformation of either RO1 or its stereoisomer Figure 4 Expressed recombinant murine AOX1 catalyzes the production of drug metabolite M1. cDNAs encoding two different allelic forms of murine Aox1 were expressed in insect cells using the baculovirus system. The indicated concentrations of RO2 were incubated with insect cell lysates (protein concentration of 1 mg ml -1 ) for 60 min, and the amount of M1 formed was determined by LC/MS/MS analysis. Both recombinant AOXs generated significant amounts of M1, whereas control lysates did not. However, the two different allelic forms of murine AOX1 catalyzed the same rate of M1 formation. Figure 5 The amount of AOX1 protein in hepatic cytosol correlates with the rate of M1 formation among the inbred strains. The amount of AOX1 protein in hepatic cytosolic preparations from eight inbred mouse strains was determined by immunoblotting. b-actin was used as a loading and normalization control. The rate of M1 formation in the eight hepatic cytosol preparations was determined as in Figure 3 . The enzyme activities were plotted along with the normalized amount of AOX1 protein in the cytosol fraction. The amount of protein was significantly correlated with enzyme activity (r 2 ¼ 0.93, P ¼ 0.0009). The amount of M1 metabolite present 1 h after incubation of RO1 (100 mM) with human liver cytosol (1 mg ml -1 ) from three donors was determined by LC/MS/MS analysis. The incubations were performed in the absence (control) or presence of 100 mM isovanillin. Each bar represents the mean and the standard error of three independent measurements for each donor.
Computational in vitro pharmacogenetics X Zhang et al (RO2) to M1 (Figure 7a) . Furthermore, this biotransformation was completely inhibited by addition of 100 mM isovanillin (Figure 7b ), confirming that this chemical inhibits human AOX1. In contrast, lysates prepared from insect cells expressing recombinant Cyp2d10 were unable to mediate this drug biotransformation reaction. Taken together, this data indicates that human AOX1 biotransformed this p38 kinase inhibitor to the principal drug metabolite formed in human subjects, which accounts for its unexpectedly rapid elimination in human subjects.
Discussion
The clinical development of a candidate p38 kinase inhibitor was terminated because of its rapid clearance in human subjects. The half-life and the metabolic profiles of this candidate drug in human subjects were vastly different in several pre-clinical species studied. Haplotype-based computational genetic analysis of the data generated using a murine in vitro biotransformation system led to the identification of AOX1 as the enzyme causing the rapid metabolism of this drug. Experiments using specific inhibitors and recombinant enzymes showed that AOX1 catalyzed the formation of the predominant 4-hydroxylated drug metabolite produced in human subjects, which was not produced in rats, dogs, or monkeys. The pattern of genetic variation within a number of haplotype blocks correlated with the rate of drug biotransformation in the panel of inbred strains analyzed. However, a very limited set of plausible candidate genes were selected by application of gene expression criteria and knowledge-based filtering 21 to identify the candidate genes that encoded enzymes that were expressed in liver.
AOXs are members of the molybdenum hydroxylase family of enzymes that are present in a wide variety of species. All AOXs are homodimers of B150 kDa monomers that contain a molybdopterin cofactor, an FAD, and two different two Fe-S centers. They are liver cytosolic enzymes with a broad substrate activity; they metabolize endogenous compounds (dopamine, serotonin, catecholamine metabolites, and retinals) 25 and many drugs, including methotrexate, zonisamide, 26 zaleplon, 27 ziprasidone, 28 pyrazinamide, and famciclovir. 29, 30 AOX enzyme activity is known to vary among different mammalian species, which explains why RO1 pharmacokinetics in human subjects differed from that in the other species evaluated. Rats and mice have low activity, and dogs have no detectable activity (reviewed in Beedham 31 ). There is also considerable interindividual variation among rat strains 32 and human beings. 33 A Gly110Ser polymorphism that may alter homodimer formation contributes to the observed 20-to 40-fold variation in AOX activity among rat strains. [34] [35] [36] An allelic difference in human AOX1 (Asn1135Ser), when combined with assessment of thiopurine methyl-transferase activity, has recently been shown to affect azathioprine response in inflammatory bowel disease. 37 In mice, we found that genetically determined differences in hepatic Aox1 mRNA and AOX1 protein expression contributed to the more subtle differences observed in this enzyme's activity across inbred mouse strains. It is also noteworthy that there are different numbers of AOX genes in the genomes of various species. Human beings have only one gene (AOX1); mouse has three (Aox1, Aox3, and Aox4); and rat has two (Aox1 and Aox2). Human AOX1 has 82% amino-acid identity with both rat and mouse AOX1. 38 AOX activity led to the rapid clearance of a novel p38 kinase inhibitor in human subjects. The pharmaceutical industry has substantial knowledge about the chemical structure of cytochrome P450 substrates and can conveniently assay cytochrome P450-mediated drug metabolism in vitro and in vivo. Although cytochrome P450 enzymes generally catalyze the oxidation of carbon atoms with a high electron density, AOXs catalyze the oxidation of electro-deficient double-bonded carbon atoms that are often present in nitrogen heterocycles. Although some drugs can serve as substrates for both types of enzymes, xenobiotics that are good substrates for one are usually poor substrates Figure 7 Expressed recombinant human AOX1 catalyzes the production of drug metabolite M1. A cDNA encoding human AOX1 was expressed in insect cells using the baculovirus system, and lysates (1 mg ml -1 ) were prepared from these cells. (a) The indicated concentrations of RO1 and RO2 were incubated with the lysates for 60 min, and the amount of M1 formed was determined by LC/MS analysis. As a control, lysates were also prepared from insect cells expressing recombinant Cyp2d10. Each bar indicates the average and standard error of three independent determinations. (b) Lysates expressing recombinant human AOX1 were incubated for 60 min with 10 mM of RO1 in the absence (control) or presence of 100 mM isovanillin. The amount of M1 formed after 60 min of incubation was determined by LC/MS analysis. Each bar indicates the average and standard error of three independent determinations.
for the other. 39 To decrease the frequency of dosing, the pharmaceutical industry is now producing novel chemical structures with long half-lives that are not substrates for cytochrome P450 enzymes. Owing to this, it is likely that enzymes such as AOX may contribute to the metabolism of these drugs. Although this is only a single example, the murine computational pharmacogenetic analysis method provides a tool that could facilitate the rapid identification and characterization of these less commonly used drug metabolism pathways. As this example shows, after a candidate has been computationally identified, the effect of a specific enzyme inhibitor can be very rapidly experimentally assessed using this in vitro drug biotransformation system.
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